multiple myeloma

Also found in: Medical, Financial, Acronyms, Encyclopedia, Wikipedia.

multiple myeloma

n.
A malignant proliferation of plasma cells in bone marrow causing numerous tumors and characterized by the presence of abnormal proteins in the blood.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

mul′tiple myelo′ma


n.
a malignant plasma cell tumor of the bone marrow that destroys bone tissue.
[1895–1900]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.multiple myeloma - myeloma that develops in several places at the same time
myeloma - a tumor of the bone marrow (usually malignant) composed of cells normally found in bone marrow
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Mentioned in
References in periodicals archive
M2 PHARMA-August 30, 2019-European Commission Approves Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
European Commission Approves Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
ENPNewswire-August 23, 2019--Genmab Announces Approval of DARZALEX in Frontline Multiple Myeloma in Japan
Genmab Announces Approval of DARZALEX in Frontline Multiple Myeloma in Japan
21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
Drug Offers Hope Against a Tough-to-Treat Blood Cancer
M2 EQUITYBITES-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
Global Banking News-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
FDA has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax for the investigational treatment of relapsed/refractory multiple myeloma. The CANOVA trial evaluates venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma positive for the translocation (11;14) abnormality.
AbbVie: FDA lifts partial clinical hold on Phase 3 study of venetoclax
OncoTracker said the acquisition of two patents offer clinical utility for multiple myeloma patients.
OncoTracker Acquires Multiple Myeloma Intellectual Property to Expand Diagnostic Testing
KEYWORDS: Newly diagnosed multiple myeloma, international scoring system, disease staging.
Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma
Evolmela is used as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
CASI Pharmaceuticals gets Chinese OK for multiple myeloma drug
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.